Blogs Articles Organizations Biography Jack's Book Contact Information Links

Navigation: SOS Sisson > Life Ethics Blog

Jack Sisson's Life Ethics Blog

We must find new ways through many ethical issues, especially regarding bioethics, medical ethics, and criminal justice. Jack Sisson's 'Life Ethics' blog focuses on numerous areas of concern, including the philosophical and ethical dilemmas surrounding stem-cell research, abortion, medical research, and health care.


From Reuters:

The U.S. Food and Drug Administration should review drugs on a regular basis for as long as they are on the market in order to catch any new safety issues, according to a report from an independent research body.

The Institute of Medicine, which often advises the government on scientific matters, said the FDA should then create a comprehensive, publicly available document that reflects risks that crop up throughout the "lifecycle" of the drug.

The FDA has been criticized for not quickly responding to dangerous side effects that become more evident after a product is brought to market, such as with Vioxx, a painkiller that Merck & Co In pulled five years after approval because of a link to heart attacks and strokes.

"It's impossible to know all the risks and benefits of a drug before approval," said Dr. Ruth Faden, co-chair of the IOM committee. The IOM called on the FDA to monitor drug safety at regular intervals over time.

The IOM's recommendations are not binding, and the FDA expressed some reservations about costs.

"We support the general concept of enabling the public to be able to clearly monitor relevant safety issues for all drugs," said FDA spokeswoman Sandy Walsh.

"However, we feel it would be very challenging to implement this recommendation within our current resources without seriously compromising other critical regulatory activities."

Currently, the FDA must only check for new safety issues after the drug has been sold for 18 months, or after it has been used by 10,000 patients, whichever is later. It relies upon reports of side effects submitted by the drugmaker, doctors or patients.

The FDA did get greater power under a 2007 law to compel drugmakers to do additional post-approval safety trials or change their labels in response to new information, rather than relying on voluntary action from the companies.

In a report last month, the FDA said it now spends as much effort and resources on tracking a drug after it is approved as it does in the pre-approval process.

It said it has required companies to do 385 post-market studies since 2008, and to change the label based on new safety information 65 times.

Dr. Faden, who is also director of the Johns Hopkins Berman Institute of Bioethics, said extensive post-approval monitoring is critical because safety concerns with a drug may only become apparent once it has been used for many years, and by thousands of patients.

"We'd like to think that when a drug is approved, the evidence is like you need to convict someone at a murder trial: rock solid and without a shadow of a doubt," said Dr. Faden.

"But that's not a criterion the FDA could ever use and get drugs out to people in a reasonable amount of time. ... Exactly how that drug will fare once it's released is an open question."

Labels: , , ,

Brain Pills
Roe v. Wade
Stem Cells
Stem Cell Fight!
Bearing Right
Moral Monkey?
Dave's site
Stem Stall
Bush the hypocrite

June 2005   July 2005   August 2005   September 2005   October 2005   December 2005   March 2006   April 2006   May 2006   July 2006   August 2006   September 2006   October 2006   November 2006   January 2007   February 2007   March 2007   April 2007   May 2007   June 2007   July 2007   August 2007   September 2007   October 2007   November 2007   December 2007   January 2008   February 2008   March 2008   March 2009   November 2009   April 2010   October 2010   April 2011   May 2011   January 2012   February 2012   March 2012   April 2012   May 2012   June 2012   November 2012   December 2012   January 2013   February 2013   March 2013   April 2013   May 2013  


This page is powered by Blogger. Isn't yours?

  Link to us: Link to us!